Phase Ib/II Clinical Study of QL1706 Combined With SOX Perioperative Treatment for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2025 New trial record